AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications
出版年份 2019 全文链接
标题
AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications
作者
关键词
-
出版物
Molecular Cancer
Volume 18, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-11-04
DOI
10.1186/s12943-019-1090-3
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
- (2019) Hirokazu Taniguchi et al. Nature Communications
- Dihydroartemisinin inhibits prostate cancer via JARID2/miR-7/miR-34a-dependent downregulation of Axl
- (2019) Juliano D. Paccez et al. Oncogenesis
- Axl is a novel target of celastrol that inhibits cell proliferation and migration, and increases the cytotoxicity of gefitinib in EGFR mutant non‑small cell lung cancer cells
- (2019) Youn Lee et al. Molecular Medicine Reports
- Quinolone antibiotic derivatives as new selective Axl kinase inhibitors
- (2019) Li Tan et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Gilteritinib: First Global Approval
- (2019) Sohita Dhillon DRUGS
- Immuno-Oncological Efficacy of RXDX-106, a Novel Small Molecule Inhibitor of the TAM (TYRO3, AXL, MER) Family of Kinases
- (2019) Yumi Yokoyama et al. CANCER RESEARCH
- S100A10 Is a Critical Mediator of GAS6/AXL–Induced Angiogenesis in Renal Cell Carcinoma
- (2019) Yiren Xiao et al. CANCER RESEARCH
- Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma
- (2018) Robert J. Motzer et al. BRITISH JOURNAL OF CANCER
- TP-0903 inhibits neuroblastoma cell growth and enhances the sensitivity to conventional chemotherapy
- (2018) Sanja Aveic et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
- (2018) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Axl inhibitors as novel cancer therapeutic agents
- (2018) Yingying Shen et al. LIFE SCIENCES
- Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors
- (2018) Julia Boshuizen et al. NATURE MEDICINE
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- EMT: Mechanisms and therapeutic implications
- (2018) Mohini Singh et al. PHARMACOLOGY & THERAPEUTICS
- Engineering Axl specific CAR and SynNotch receptor for cancer therapy
- (2018) Jang Hwan Cho et al. Scientific Reports
- The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression
- (2018) Marie-Anne Goyette et al. Cell Reports
- Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
- (2018) Thomas Powles et al. BRITISH JOURNAL OF CANCER
- Clinical Profile of Gilteritinib in Japanese Patients with Relapsed/Refractory AML: an Open-Label Phase 1 Study
- (2018) Kensuke Usuki et al. CANCER SCIENCE
- Aptamer-miR-34c conjugate affects cell proliferation of non-small cell lung cancer cells
- (2018) Valentina Russo et al. Molecular Therapy-Nucleic Acids
- AXL Mediates Esophageal Adenocarcinoma Cell Invasion through Regulation of Extracellular Acidification and Lysosome Trafficking
- (2018) Selma Maacha et al. NEOPLASIA
- Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients
- (2018) Valentín García-Gutiérrez et al. ANNALS OF HEMATOLOGY
- 1452PCombination of the S49076 with gefitinib in NSCLC patients progressing on EGFR-TKI and harboring MET/AXL dysregulation
- (2018) S Viteri et al. ANNALS OF ONCOLOGY
- Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–small-cell Lung Carcinoma
- (2018) Beth A. Hellerstedt et al. Clinical Lung Cancer
- A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study
- (2018) Ursula A. Matulonis et al. GYNECOLOGIC ONCOLOGY
- Therapeutic activity of DCC‐2036, a novel tyrosine kinase inhibitor, against triple‐negative breast cancer patient‐derived xenografts by targeting AXL/MET
- (2018) Yingying Shen et al. INTERNATIONAL JOURNAL OF CANCER
- Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours
- (2017) Patrick Schöffski et al. EUROPEAN JOURNAL OF CANCER
- A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma
- (2017) Ignace B. Vergote et al. EUROPEAN JOURNAL OF CANCER
- First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours
- (2017) Jordi Rodon et al. EUROPEAN JOURNAL OF CANCER
- Development of crizotinib, a rationally designed tyrosine kinase inhibitor for non-small cell lung cancer
- (2017) Candice C. Poon et al. INTERNATIONAL JOURNAL OF CANCER
- n-Butylidenephthalide Regulated Tumor Stem Cell Genes EZH2/AXL and Reduced Its Migration and Invasion in Glioblastoma
- (2017) Ssu-Yin Yen et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Drug Resistance Driven by Cancer Stem Cells and Their Niche
- (2017) Marta Prieto-Vila et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping
- (2017) S. Betty Yan et al. INVESTIGATIONAL NEW DRUGS
- Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
- (2017) Masamichi Mori et al. INVESTIGATIONAL NEW DRUGS
- Epithelial-mesenchymal transition (EMT): A biological process in the development, stem cell differentiation, and tumorigenesis
- (2017) Tong Chen et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Phenotypic screening identifies Axl kinase as a negative regulator of an alveolar epithelial cell phenotype
- (2017) Naoya Fujino et al. LABORATORY INVESTIGATION
- Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
- (2017) Alexander E Perl et al. LANCET ONCOLOGY
- The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy
- (2017) Céline Clémenson et al. MOLECULAR CANCER THERAPEUTICS
- PI3K/Akt and ERK/MAPK Signaling Promote Different Aspects of Neuron Survival and Axonal Regrowth Following Rat Facial Nerve Axotomy
- (2017) Haitao Huang et al. NEUROCHEMICAL RESEARCH
- Mistletoe ( Viscum album ) extract targets Axl to suppress cell proliferation and overcome cisplatin- and erlotinib-resistance in non-small cell lung cancer cells
- (2017) Soyoung Kim et al. PHYTOMEDICINE
- The receptor tyrosine kinase AXL promotes migration and invasion in colorectal cancer
- (2017) Diana J. Uribe et al. PLoS One
- Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies
- (2017) Marie Schoumacher et al. Current Oncology Reports
- MicroRNA-34a dependent regulation of AXL controls the activation of dendritic cells in inflammatory arthritis
- (2017) Mariola Kurowska-Stolarska et al. Nature Communications
- Soluble Axl is an accurate biomarker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter analysis
- (2017) Mirko Dengler et al. Oncotarget
- A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196
- (2017) Natasha B. Leighl et al. Oncotarget
- Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity
- (2017) Stanley G. Kimani et al. Scientific Reports
- Axl Mediates ZIKA Virus Entry in Human Glial Cells and Modulates Innate Immune Responses
- (2017) Laurent Meertens et al. Cell Reports
- From Resistance to Sensitivity: Insights and Implications of Biphasic Modulation of Autophagy by Sunitinib
- (2017) Amal Kamal Abdel-Aziz et al. Frontiers in Pharmacology
- Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models
- (2017) Pinar Kanlikilicer et al. Molecular Therapy-Nucleic Acids
- Crizotinib: from discovery to accelerated development to front-line treatment
- (2016) F. Blackhall et al. ANNALS OF ONCOLOGY
- Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer
- (2016) Daniel Rayson et al. BREAST CANCER RESEARCH AND TREATMENT
- Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study
- (2016) Sara M. Tolaney et al. BREAST CANCER RESEARCH AND TREATMENT
- EMT: 2016
- (2016) M. Angela Nieto et al. CELL
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- (2016) Willy Hugo et al. CELL
- A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
- (2016) Thomas C.C. Yau et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy
- (2016) M. Scaltriti et al. CLINICAL CANCER RESEARCH
- Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor–Sensitive and -Resistant Chronic Myeloid Leukemia
- (2016) Isabel Ben-Batalla et al. CLINICAL CANCER RESEARCH
- Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis
- (2016) Wilhem Leconet et al. CLINICAL CANCER RESEARCH
- Gas6/AXL Signaling Regulates Self-Renewal of Chronic Myelogenous Leukemia Stem Cells by Stabilizing β-Catenin
- (2016) Yanli Jin et al. CLINICAL CANCER RESEARCH
- Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells
- (2016) Cristina Corno et al. CURRENT MEDICINAL CHEMISTRY
- Phenotypic chemical screening using a zebrafish neural crest EMT reporter identifies retinoic acid as an inhibitor of epithelial morphogenesis
- (2016) Laura Jimenez et al. Disease Models & Mechanisms
- Sunitinib for the treatment of thyroid cancer
- (2016) José-Manuel Gómez-Sáez EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Sunitinib in kidney cancer: 10 years of experience and development
- (2016) Elise Nassif et al. Expert Review of Anticancer Therapy
- Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies
- (2016) Mihalis S. Kariolis et al. JOURNAL OF CLINICAL INVESTIGATION
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
- (2016) Toni K Choueiri et al. LANCET ONCOLOGY
- MNK Inhibition Disrupts Mesenchymal Glioma Stem Cells and Prolongs Survival in a Mouse Model of Glioblastoma
- (2016) J. B. Bell et al. MOLECULAR CANCER RESEARCH
- AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers
- (2016) Kavitha Balaji et al. MOLECULAR CANCER RESEARCH
- Targeting c-MET by LY2801653 for treatment of cholangiocarcinoma
- (2016) Samarpita Barat et al. MOLECULAR CARCINOGENESIS
- Targeting Epithelial–Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer
- (2016) Bowen Du et al. MOLECULES
- Anexelekto (AXL) Increases Resistance to EGFR-TKI and Activation of AKT and ERK1/2 in Non-Small Cell Lung Cancer Cells
- (2016) Yaqiong Tian et al. ONCOLOGY RESEARCH
- The TAM family receptor tyrosine kinase TYRO3 is a negative regulator of type 2 immunity
- (2016) P. Y. Chan et al. SCIENCE
- The AXL receptor tyrosine kinase is associated with adverse prognosis and distant metastasis in esophageal squamous cell carcinoma
- (2016) Min-Shu Hsieh et al. Oncotarget
- Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo
- (2016) Julia Onken et al. Oncotarget
- Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers
- (2016) Erik S. Linklater et al. Oncotarget
- Axl-EGFR receptor tyrosine kinase hetero-interaction provides EGFR with access to pro-invasive signalling in cancer cells
- (2016) M Vouri et al. Oncogenesis
- AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas
- (2015) Caitlin D. May et al. BMC CANCER
- AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas
- (2015) Moshe Elkabets et al. CANCER CELL
- Tackling Crizotinib Resistance: The Pathway from Drug Discovery to the Pediatric Clinic
- (2015) E. R. Tucker et al. CANCER RESEARCH
- Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors
- (2015) S. Sinha et al. CLINICAL CANCER RESEARCH
- AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma
- (2015) T. M. Brand et al. CLINICAL CANCER RESEARCH
- Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas
- (2015) R. A. Toledo et al. CLINICAL CANCER RESEARCH
- Pancreatic neuroendocrine tumors: a review
- (2015) Kate Young et al. Future Oncology
- Curcumin-induced downregulation of Axl receptor tyrosine kinase inhibits cell proliferation and circumvents chemoresistance in non-small lung cancer cells
- (2015) KYUNG-CHAN KIM et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective
- (2015) Samuel H. Myers et al. JOURNAL OF MEDICINAL CHEMISTRY
- Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia
- (2015) I-K Park et al. LEUKEMIA
- Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia
- (2015) Viralkumar Patel et al. LEUKEMIA & LYMPHOMA
- The Axl receptor tyrosine kinase is a discriminator of macrophage function in the inflamed lung
- (2015) T Fujimori et al. Mucosal Immunology
- Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells
- (2015) Devon A. Lawson et al. NATURE
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- (2015) Pasi A. Jänne et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- TAMing resistance to multi-targeted kinase inhibitors through Axl and Met inhibition
- (2015) D J Pinato et al. ONCOGENE
- ALK inhibitor resistance in ALKF1174L-driven neuroblastoma is associated with AXL activation and induction of EMT
- (2015) D N Debruyne et al. ONCOGENE
- MiR-34a suppresses ovarian cancer proliferation and motility by targeting AXL
- (2015) Rui Li et al. TUMOR BIOLOGY
- AXL is an oncotarget in human colorectal cancer
- (2015) Erika Martinelli et al. Oncotarget
- Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST)
- (2015) Daruka Mahadevan et al. Oncotarget
- Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma
- (2015) Parag P. Patwardhan et al. Oncotarget
- Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells
- (2015) Maeva Dufies et al. Oncotarget
- AXL kinase as a novel target for cancer therapy
- (2015) Xiaoliang Wu et al. Oncotarget
- Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?
- (2014) Zheng Zhao et al. ACS Chemical Biology
- Synthesis of 2′,3′,4′-trihydroxyflavone (2-D08), an inhibitor of protein sumoylation
- (2014) Yeong Sang Kim et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Crosstalk between ERK, AKT, and cell survival
- (2014) Paul Dent CANCER BIOLOGY & THERAPY
- Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors
- (2014) Monica Mita et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- AXL Mediates Resistance to Cetuximab Therapy
- (2014) T. M. Brand et al. CANCER RESEARCH
- UNC2025, a Potent and Orally Bioavailable MER/FLT3 Dual Inhibitor
- (2014) Weihe Zhang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Axl Kinase as a Key Target for Oncology: Focus on Small Molecule Inhibitors
- (2014) C. Feneyrolles et al. MOLECULAR CANCER THERAPEUTICS
- The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells
- (2014) Magdalena Paolino et al. NATURE
- An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis
- (2014) Mihalis S Kariolis et al. Nature Chemical Biology
- Diversification of TAM receptor tyrosine kinase function
- (2014) Anna Zagórska et al. NATURE IMMUNOLOGY
- Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET
- (2014) Erinn B. Rankin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- BMS-777607 promotes megakaryocytic differentiation and induces polyploidization in the CHRF-288-11 cells
- (2014) Retno Wahyu Nurhayati et al. Human Cell
- TAM receptors in apoptotic cell clearance, autoimmunity, and cancer
- (2013) Khanh-Quynh Nguyen et al. AUTOIMMUNITY
- Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients
- (2013) Ju Han et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma
- (2013) I. Ben-Batalla et al. BLOOD
- Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target
- (2013) I.-K. Park et al. BLOOD
- Dramatic Antitumor Effects of the Dual MET/RON Small-Molecule Inhibitor LY2801653 in Non-Small Cell Lung Cancer
- (2013) I. Kawada et al. CANCER RESEARCH
- TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase
- (2013) X. Wang et al. CANCER RESEARCH
- MET and AXL Inhibitor NPS-1034 Exerts Efficacy against Lung Cancer Cells Resistant to EGFR Kinase Inhibitors Because of MET or AXL Activation
- (2013) J. K. Rho et al. CANCER RESEARCH
- Gas6/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma
- (2013) Hsin-Jung Lee et al. CARCINOGENESIS
- Inhibition of Tumor Growth and Metastasis in Non-Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET
- (2013) W. Wu et al. CLINICAL CANCER RESEARCH
- The Disparate Twins: A Comparative Study of CXCR4 and CXCR7 in SDF-1α–Induced Gene Expression, Invasion and Chemosensitivity of Colon Cancer
- (2013) Doreen Heckmann et al. CLINICAL CANCER RESEARCH
- Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer
- (2013) David Viola et al. Future Oncology
- NPS-1034, a novel MET inhibitor, inhibits the activated MET receptor and its constitutively active mutants
- (2013) Jae-Sik Shin et al. INVESTIGATIONAL NEW DRUGS
- Lactate Engages Receptor Tyrosine Kinases Axl, Tie2, and Vascular Endothelial Growth Factor Receptor 2 to Activate Phosphoinositide 3-Kinase/Akt and Promote Angiogenesis
- (2013) Guo-Xiang Ruan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
- (2013) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib in Progressive Medullary Thyroid Cancer
- (2013) Rossella Elisei et al. JOURNAL OF CLINICAL ONCOLOGY
- Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents
- (2013) S. Sharma et al. MOLECULAR CANCER THERAPEUTICS
- UNC569, a Novel Small-Molecule Mer Inhibitor with Efficacy against Acute Lymphoblastic LeukemiaIn VitroandIn Vivo
- (2013) Sandra Christoph et al. MOLECULAR CANCER THERAPEUTICS
- Axl Mediates Acquired Resistance of Head and Neck Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Erlotinib
- (2013) Keith M. Giles et al. MOLECULAR CANCER THERAPEUTICS
- S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab
- (2013) M. F. Burbridge et al. MOLECULAR CANCER THERAPEUTICS
- AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells
- (2013) M K Asiedu et al. ONCOGENE
- Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy
- (2013) W Leconet et al. ONCOGENE
- The receptor tyrosine kinase Axl regulates cell–cell adhesion and stemness in cutaneous squamous cell carcinoma
- (2013) M A Cichoń et al. ONCOGENE
- TAZ Expression as a Prognostic Indicator in Colorectal Cancer
- (2013) Hiu-Fung Yuen et al. PLoS One
- Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
- (2013) Manish A. Shah et al. PLoS One
- Paradoxical role of the proto-oncogene Axl and Mer receptor tyrosine kinases in colon cancer
- (2013) L. Bosurgi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Receptor AXL Diversifies EGFR Signaling and Limits the Response to EGFR-Targeted Inhibitors in Triple-Negative Breast Cancer Cells
- (2013) A. S. Meyer et al. Science Signaling
- Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
- (2012) H. J. Khoury et al. BLOOD
- A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors
- (2012) Raoul Tibes et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Abstract 1790: The combination of MGCD265, a Met/VEGFR inhibitor in clinical development, and erlotinib potently inhibits tumor growth by altering multiple pathways including glycolysis
- (2012) Claire Bonfils et al. CANCER RESEARCH
- Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation
- (2012) Yao Dai et al. CLINICAL & EXPERIMENTAL METASTASIS
- An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
- (2012) L. A. Byers et al. CLINICAL CANCER RESEARCH
- Activity-based kinase profiling of approved tyrosine kinase inhibitors
- (2012) Daisuke Kitagawa et al. GENES TO CELLS
- LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models
- (2012) S. Betty Yan et al. INVESTIGATIONAL NEW DRUGS
- Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma
- (2012) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial
- (2012) David C. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting Axl With an High-affinity Inhibitory Aptamer
- (2012) Laura Cerchia et al. MOLECULAR THERAPY
- Promotion of Glioblastoma Cell Motility by Enhancer of Zeste Homolog 2 (EZH2) Is Mediated by AXL Receptor Kinase
- (2012) Martina Ott et al. PLoS One
- Discovery of Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia
- (2012) Jing Liu et al. ACS Medicinal Chemistry Letters
- Transcriptional activation of the Axl and PDGFR-α by c-Met through a ras- and Src-independent mechanism in human bladder cancer
- (2011) Chen-Yun Yeh et al. BMC CANCER
- Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036
- (2011) Wayne W. Chan et al. CANCER CELL
- VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
- (2011) W.-K. You et al. CANCER RESEARCH
- Activation of TYRO3/AXL Tyrosine Kinase Receptors in Thyroid Cancer
- (2011) E. Avilla et al. CANCER RESEARCH
- Activated MET Is a Molecular Prognosticator and Potential Therapeutic Target for Malignant Peripheral Nerve Sheath Tumors
- (2011) K. E. Torres et al. CLINICAL CANCER RESEARCH
- The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model
- (2011) Erik R Sampson et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Galectin-3 is a new MerTK-specific eat-me signal
- (2011) Nora B. Caberoy et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Loss of the receptor tyrosine kinase Axl leads to enhanced inflammation in the CNS and delayed removal of myelin debris during Experimental Autoimmune Encephalomyelitis
- (2011) Jason G Weinger et al. Journal of Neuroinflammation
- Differential 18F-FDG and 3'-Deoxy-3'-18F-Fluorothymidine PET Responses to Pharmacologic Inhibition of the c-MET Receptor in Preclinical Tumor Models
- (2011) C. Cullinane et al. JOURNAL OF NUCLEAR MEDICINE
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- Comprehensive analysis of kinase inhibitor selectivity
- (2011) Mindy I Davis et al. NATURE BIOTECHNOLOGY
- Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer
- (2011) G Mudduluru et al. ONCOGENE
- The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio- and chemo-therapies in part by inhibiting homologous recombination
- (2011) Helen Zhao et al. RADIOTHERAPY AND ONCOLOGY
- Design, Synthesis, and Biological Evaluation of a Series of Novel AXL Kinase Inhibitors
- (2011) Alexis Mollard et al. ACS Medicinal Chemistry Letters
- PMA up-regulates the transcription of Axl by AP-1 transcription factor binding to TRE sequences via the MAPK cascade in leukaemia cells
- (2010) Giridhar Mudduluru et al. BIOLOGY OF THE CELL
- The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy
- (2010) A. K. Ghosh et al. BLOOD
- Induction, regulation, and biologic function of Axl receptor tyrosine kinase in Kaposi sarcoma
- (2010) R. Liu et al. BLOOD
- The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target
- (2010) Jan-Bart M. Koorstra et al. CANCER BIOLOGY & THERAPY
- AXL Is an Essential Factor and Therapeutic Target for Metastatic Ovarian Cancer
- (2010) E. B. Rankin et al. CANCER RESEARCH
- R428, a Selective Small Molecule Inhibitor of Axl Kinase, Blocks Tumor Spread and Prolongs Survival in Models of Metastatic Breast Cancer
- (2010) S. J. Holland et al. CANCER RESEARCH
- A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2
- (2010) J. P. Eder et al. CLINICAL CANCER RESEARCH
- TAM receptor signaling and autoimmune disease
- (2010) Carla V Rothlin et al. CURRENT OPINION IN IMMUNOLOGY
- Tubby and tubby-like protein 1 are new MerTK ligands for phagocytosis
- (2010) Nora B Caberoy et al. EMBO JOURNAL
- Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors
- (2010) Rachel MA Linger et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Myeloid Zinc Finger 1 Induces Migration, Invasion, and In vivo Metastasis through Axl Gene Expression in Solid Cancer
- (2010) G. Mudduluru et al. MOLECULAR CANCER RESEARCH
- BMS-777607, a Small-Molecule Met Kinase Inhibitor, Suppresses Hepatocyte Growth Factor-Stimulated Prostate Cancer Metastatic Phenotype In vitro
- (2010) Y. Dai et al. MOLECULAR CANCER THERAPEUTICS
- AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma
- (2010) M Z Xu et al. ONCOGENE
- An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies
- (2010) X Ye et al. ONCOGENE
- MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer
- (2009) Wenqing Qi et al. BMC CANCER
- Therapeutic antibodies: successes, limitations and hopes for the future
- (2009) Patrick Chames et al. BRITISH JOURNAL OF PHARMACOLOGY
- SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo
- (2009) Jennifer P. Arbitrario et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases
- (2009) F. Qian et al. CANCER RESEARCH
- Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL
- (2009) L. Liu et al. CANCER RESEARCH
- Epithelial-Mesenchymal Transitions in Development and Disease
- (2009) Jean Paul Thiery et al. CELL
- Epithelial-Mesenchymal Transitions in development and disease: old views and new perspectives
- (2009) M. Angela Nieto INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY
- Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease
- (2009) Hervé Acloque et al. JOURNAL OF CLINICAL INVESTIGATION
- Discovery ofN-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily
- (2009) Gretchen M. Schroeder et al. JOURNAL OF MEDICINAL CHEMISTRY
- Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis
- (2009) Y Li et al. ONCOGENE
- Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival
- (2009) C. Gjerdrum et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells
- (2009) James W Welsh et al. Radiation Oncology
- Discovery of a potent and selective Aurora kinase inhibitor
- (2008) Johan D. Oslob et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- The human receptor tyrosine kinase Axl gene - promoter characterization and regulation of constitutive expression by Sp1, Sp3, and CpG methylation
- (2008) Giridhar Mudduluru et al. BIOSCIENCE REPORTS
- Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia
- (2008) Chih-Chen Hong et al. CANCER LETTERS
- AXL Is a Potential Target for Therapeutic Intervention in Breast Cancer Progression
- (2008) Y.-X. Zhang et al. CANCER RESEARCH
- Molecular Targets in Gastrointestinal Stromal Tumors (GIST) Therapy
- (2008) C. Braconi et al. CURRENT CANCER DRUG TARGETS
- Discovery of Pyrrolopyridine−Pyridone Based Inhibitors of Met Kinase: Synthesis, X-ray Crystallographic Analysis, and Biological Activities
- (2008) Kyoung Soon Kim et al. JOURNAL OF MEDICINAL CHEMISTRY
- SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells
- (2008) A. Vultur et al. MOLECULAR CANCER THERAPEUTICS
- Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-κB and Brg-1
- (2008) K-Y Tai et al. ONCOGENE
- Nonclinical Safety Evaluation of Sunitinib: A Potent Inhibitor of VEGF, PDGF, KIT, FLT3, and RET Receptors
- (2008) Shem Patyna et al. TOXICOLOGIC PATHOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started